4th Annual Brain Tumor Symposium:
The History of Neuro-Oncology and its Evolution in Medicine and Surgery
October 31, 2014
Hyatt Regency Philadelphia at Penn's Landing
201 South Columbus Blvd.
Philadelphia, PA 19106
Featuring Guest Speakers:
Howard A. Fine, MD
Anne Murnick Cogan and David H. Cogan Professor of Oncology
Director, Division of Hematology & Medical Oncology
Director, NYU Brain Tumor Center
Deputy Director, NYU Cancer Institute
Director, Bellevue Hospital Cancer Center
The New York University (NYU) Langone Medical Center
NYU Cancer Institute
Eugene S. Flamm, MD
Jeffrey P. Bergstein Chair in Neurological Surgery
Montefiore Medical Center
This innovative course will be of interest to all specialists working in the field of neuro-oncology: neurosurgeons, neurologists, neuro-radiologists, neuropathologists, family physicians, nurses and trainees.
This CME Conference offers participants a unique opportunity to hear expert clinician leaders relate their knowledge of the field of neuro-oncology and its evolution. Malignant brain tumors have always been segregated from mainstream oncology because of the unique challenges presented by tumors in the central nervous system. Until only recently, there was no representation of Neuro-Oncology in the National Cancer Institute until the Neuro-Oncology Branch was formed just recently in 2000. In the Morning Session, lectures will be devoted to an in depth review of the origins of neuro-oncology and how it has evolved in medicine and surgery over the past 60 years. Participants will gain an understanding of how the discipline has evolved and what milestones have redirected treatment. In the Afternoon Session, leading practitioners provide evidence for care decisions based on historical precedents and lessons learned from clinical trials, geared for both physicians and nurses.
The didactic presentations will allow participants to observe and question faculty practitioners as they absorb this history and view current innovations based on this historical foundation.
Sidney Kimmel Medical College at Thomas Jefferson University is accredited by the ACCME to provide continuing medical education for physicians.
Sidney Kimmel Medical College at Thomas Jefferson University designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Thomas Jefferson University Hospital is an approved provider of Continuing Nursing Education (CNE) by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 6.3 nursing contact hours will be awarded for this program. The participant must attend the entire program to be eligible for full contact hour credit.
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing medical education activities sponsored by Sidney Kimmel Medical College are expected to disclose to the activity audience any real or apparent conflict(s) of interest related to the content of their presentation(s). Full disclosure of faculty relationships will be made at this activity.
As an integral part of Jefferson Hospital for Neuroscience, the region's only dedicated hospital for neuroscience, the Department of Neurological Surgery at Jefferson University Hospital is one of the busiest academic neurosurgical programs in the country, offering state-of-the-art treatment to patients with neurological diseases affecting the brain and spine, such as brain tumors, spinal disease, vascular brain diseases, epilepsy, pain, Parkinson's disease and many other neurological disorders (http://www.jefferson.edu/jmc/departments/neurosurgery.html).
The Kimmel Cancer Center (KCC) was founded in 1991 and is one of a select group of cancer centers in the nation designated by the National Cancer Institute. Today, the KCC has approximately 150 members that include physicians and scientists dedicated to discovery and development of novel approaches for cancer treatment. The mission of the Kimmel Cancer Center, a National Cancer Institute-designated cancer center, is to:
- make transformational discoveries of the cellular and molecular biology of the malignant process and the individual's and society's response to it
- effectively translate the latest research discoveries and clinical trials to provide the highest quality of care to all patients including those of diverse ethnic and racial populations
- provide expert and humanitarian care to cancer patients, their families, and those at risk